Decreases in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers: HPV-IMPACT, 2008 to 2019
Authors:
- Ruth StefanosRSRuth Stefanos
- Julia W. GarganoJulia W. Gargano
- Linda M. NiccolaiLinda M. Niccolai
- Jessica L. CastilhoJessica L. Castilho
- Ina U. ParkIPIna U. Park
- Erica A. BostickErica A. Bostick
- Sara EhlersSESara Ehlers
- Sheelah BlankenshipSBSheelah Blankenship
- Monica M. BrackneyMonica M. Brackney
- Kameny ChanKCKameny Chan
- RaeAnne KurtzRKRaeAnne Kurtz
- Erin WhitneyEWErin Whitney
- 6 May 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (6) , 913-920
Abstract
Background: Monitoring human papillomavirus (HPV) types detected in cervical precancers has been one approach to evaluate HPV vaccination impact in the United States. During 2008 to 2014, the proportion of cervical precancers positive for HPV16/18 decreased overall and among some demographic and histologic subgroups. This updated analysis describes trends through 2019. Methods: We analyzed cervical precancers among women 20 to 39 years of age from a five-site, population-based surveillance program for cervical intraepithelial neoplasia grade 2 or higher and adenocarcinoma in situ (AIS; collectively CIN2+). Available archived diagnostic tissue was tested for HPV16, HPV18, and other HPV types. We evaluated the average annual percent change (AAPC) in the proportion of cervical precancers with HPV16 or 18 detected overall and by vaccination status, age group, diagnosis, race/ethnicity, and surveillance site. Results: During 2008 to 2019, 17,323 CIN2+ cases had valid typing results. The proportion of cases positive for HPV16/18 significantly decreased by 3.6% per year. The largest decrease occurred among cases in vaccinated women (AAPC = −8.9), with smaller but still significant decreases among unvaccinated women (AAPC = −2.3). Significant decreases were observed among all subgroups evaluated, except women 35 to 39 years of age, AIS, and Asian women. Conclusions: During 2008 to 2019, decreases in the proportion of CIN2+ cases that were HPV16/18 positive among vaccinated and unvaccinated women and in most subgroups evaluated suggest direct and indirect HPV vaccination impact. Impact: HPV vaccination impact on precancers is prognostic of future decreases in cervical cancer. Continued monitoring can enable evaluation of vaccination impact in population subgroups.Keywords
All Related Versions
Funding Information
- Centers for Disease Control and Prevention (U50CK000643)
- Centers for Disease Control and Prevention (U50CK000644)
- Centers for Disease Control and Prevention (U50CK000650)
- Centers for Disease Control and Prevention (U50CK000651)
- Centers for Disease Control and Prevention (U50CK000652)
This publication has 33 references indexed in Scilit:
- Population-Based Incidence of Cervical Intraepithelial Neoplasia Across 14 Years of HPV VaccinationJAMA Oncology, 2024
- Evaluation of the Novaplex II HPV28 Detection Assay for HPV Typing in Formalin-Fixed, Paraffin-Embedded TissuesThe Journal of Molecular Diagnostics, 2023
- HPV type‐specific trends in cervical precancers in the United States, 2008 to 2016International Journal of Cancer, 2022
- Recalibrating the Use of Race in Medical ResearchJAMA, 2021
- HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccinationVaccine, 2020
- Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysisThe Lancet, 2019
- Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015International Journal of Cancer, 2019
- Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007–2016Vaccine, 2018
- Ten Years of Human Papillomavirus Vaccination in the United StatesAcademic Pediatrics, 2018
- Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine EraJAMA Oncology, 2017